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The idea of clinical governance within the NHS is 
fairly recent, but one of the fundamental elements 
of this idea is the use of outcome measures and 
their importance in clinical practice to evaluate 
treatment (Chartered Society of Physiotherapy 
(CSP), 2001). The demand for evidence-based 
treatment and cost-effectiveness has challenged 
many traditional practices and has brought 
pressures on physiotherapists to change attitudes 
and develop skills (Bower & Ashburn, 1998). As 
a result of the increasing call for outcome-oriented 
and evidence-based practice, there are now an 
increasing number of paediatric measures and 
instruments specifically geared to the paediatric 
rehabilitation profession (Helders et al, 2003). 
Cerebral Palsy (CP) presents as a disorder of 
motor function due to a non-progressive (static) 
lesion of the developing brain and children with 
CP often have problems in addition to disorders of 
movement and posture (Budd & Gardiner, 1999). 
75% of all cases of CP present with spasticity 
(Pope et al, 1990). The management of spasticity 
is complex and physiotherapy has a large role to 
play in this process. Botulinum A Toxin (BTX-A) 
has come to the fore in recent years as one method 
of treating spasticity (Jankovic & Schwartz, 
1995).  
The questionnaire was designed in two sections: 
to collect demographic information, and to collect 
data relating to the study objectives. The 
questionnaire was designed to be as short as 
possible (Stone, 1993) while still being 
comprehensive as a form of data collection.  
100 centres were randomly selected from the 
Directory of Child Development Services and 
questionnaires sent with a covering letter and a 
SAE. 
 
The data was analysed using descriptive statistics 
100 letters were sent out initially, and 60 were 
returned, of which 49 consented to participate in 
the study but only 40 were eligible for use.  
The mean number of children (n=40) on caseloads 
was 22 patients with spastic CP which represented 
31% of their total caseload and of these only 27% 
(6 children) were receiving BTX-A treatment. Out 
of the 40 respondents (n=40), 70% (28) used 
outcome measures in the assessment or treatment 
evaluation of children with spastic CP receiving 
BTX. Those used are shown in Figure 1. 
Table 1 shows that the most highly ranked 
outcome measure was video analysis for the 
purpose of assessment, and goniometry for the 
purpose of treatment evaluation. These 2 
measures, along with the GMFM were the 3 most 
highly ranked in both categories by respondents. 
The 3 commonest reasons for these choices were 
validity, reliability and that training had been 
received.  
 
Whilst 70% of respondents used outcome 
measures, 30% did not. The CSP (2000) has 2 
core physiotherapy standards that relate to the use 
of outcome measures ‘….standardised, valid, 
reliable and responsive outcome measure….’ 
and that ‘the treatment plan is constantly 
evaluated to ensure that it is effective and 
relevant…’ This could imply that those 
respondents who did not use any outcome 
measure are practising outside the standards set by 
the professional body. This could indicate training 
needs, time factors and feasibility issues of the use 
of outcome measures in clinical practice.  
The majority of respondents (70%) are using 
outcome measures in the assessment and 
treatment evaluation of children with spasticity 
receiving BTX-A. The most commonly used are 
video, goniometry and GMFM. There is a concern 
that a minority of practicing physiotherapists are 
not choosing to use outcome measures as part of 
this evaluation. If evidence based practice can be 
developed to improve quality assurance in the 
National Health Service, physiotherapists  can 
show they are clinically effective by using the 
tools that have been designed by rigorous 
methods. 
The authors would like to thank the respondents 
for giving their time to participate in this study. 
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To identify which outcome measures are used by 
physiotherapists in children’s centres within the 
UK during the assessment and treatment 
evaluation of CP children with spasticity 
receiving BTX-A injection. 
 
Figure 1. Bar chart showing outcome measures used by 
respondents
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Key: 
Series 1 - the number of respondents who have used the 
measure in the last 3 months   
Series 2 – the number of respondents who have ever 
used the measure 
GMPM – Gross Motor Performance Measure  
GMFM – Gross Motor Function Measure 
MAS – Modified Ashworth Scale    
PEDI – Paediatric Evaluation of Disability Inventory 
Amb. speed – Ambulation Speed  
Wee-FIM – Wee Functional Independence Measure 
PCI – Physiological Cost Index 
Tardieu – Tardieu Measure of Spasticity  
   
 
 
 
 
Discussion 
Outcome  
Measure 
Assessment 
Treatment  
Evaluation 
GMPM 4 6 
GMFM 35 32 
MAS 8 11 
Goniometer 46 49 
Video 47 41 
PEDI 2 2 
Amb. 
Speed 
1 1 
Wee-FIM 0 0 
PCI 3 3 
Tardieu 8 9 
Other 14 14 
 
Table 1. Score for the frequency of each 
Outcome measure used in Assessment and 
Treatment Evaluation 
^ 
